HF
FDMT icon

HRT Financial’s 4D Molecular Therapeutics FDMT Stock Holding History

HRT Financial’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-43,903
Closed -$162K – 3083
2025
Q2 		$162K Sell
43,903
-6,497
-13% -$22.8K ﹤0.01% 2117
2025
Q1 		$162K Sell
50,400
-33,019
-40% -$156K ﹤0.01% 2072
2024
Q4 		$464K Buy
+83,419
New +$655K ﹤0.01% 1485
2024
Q1 		– Sell
-9,991
Closed -$202K – 2546
2023
Q4 		$202K Sell
9,991
-16,026
-62% -$211K ﹤0.01% 1794
2023
Q3 		$331K Buy
+26,017
New +$435K ﹤0.01% 1613
2022
Q3 		– Sell
-37,461
Closed -$261K – 3013
2022
Q2 		$261K Buy
+37,461
New +$364K ﹤0.01% 2111

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

HRT Financial's FDMT Position: Q3 2025 in Review

HRT Financial sold out of 4D Molecular Therapeutics (FDMT) in Q3 2025, closing a stake of 43,903 shares — an estimated $162K sold.

HRT Financial first reported a position in FDMT in Q2 2022 and held it in 6 quarters. The position peaked at $464K in Q4 2024. 134 funds tracked by Wall St. Rank hold FDMT as of Q3 2025.

  • HRT Financial reported no remaining 4D Molecular Therapeutics position as of Q3 2025 after selling out during the quarter.
  • HRT Financial sold 43,903 4D Molecular Therapeutics shares in Q3 2025, an estimated $162K.
  • HRT Financial first reported a position in 4D Molecular Therapeutics in Q2 2022 and held it in 6 quarters.
  • HRT Financial's 4D Molecular Therapeutics position peaked at $464K in Q4 2024.
  • 134 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2025.

Based on HRT Financial's 13F filing for Q3 2025, filed 14 Nov 2025.